Litcius/Paper detail

Triazole-Resistant Aspergillus fumigatus in an Israeli Patient with Chronic Cavitary Pulmonary Aspergillosis Due to a Novel E306K Substitution in Hmg1

Mariana Handelman, Alma Morogovsky, Wei Liu, Ronen Ben‐Ami, Nir Osherov

2021Antimicrobial Agents and Chemotherapy10 citationsDOIOpen Access PDF

Abstract

Triazole resistance in the pathogenic mold Aspergillus fumigatus has increased worldwide, posing a growing therapeutic challenge. Recently, mutations in the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase gene ( hmg1 ) have been associated with triazole resistance. Here, we describe a novel E306K triazole resistance-conferring mutation in the HMG-CoA reductase gene from an Israeli patient with chronic cavitary pulmonary aspergillosis (CCPA).

Topics & Concepts

Aspergillus fumigatusReductaseAspergillosisTriazoleAspergillusPulmonary aspergillosisDrug resistanceMicrobiologyMutationGeneBiologyMedicineEnzymeChemistryBiochemistryImmunologyOrganic chemistryAntifungal resistance and susceptibilityPeptidase Inhibition and AnalysisFungal Infections and Studies
Triazole-Resistant Aspergillus fumigatus in an Israeli Patient with Chronic Cavitary Pulmonary Aspergillosis Due to a Novel E306K Substitution in Hmg1 | Litcius